Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Cannabidiol for Drug-Resistant Epilepsies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03014440
Expanded Access Status : No longer available
First Posted : January 9, 2017
Last Update Posted : April 4, 2017
Sponsor:
Collaborators:
University of Pittsburgh
Geisinger Clinic
Information provided by (Responsible Party):
Eric Marsh, MD, Children's Hospital of Philadelphia

Tracking Information
First Submitted Date January 5, 2017
First Posted Date January 9, 2017
Last Update Posted Date April 4, 2017
 
Descriptive Information
Brief Title Study of Cannabidiol for Drug-Resistant Epilepsies
Brief Summary The purpose of this study is to determine if cannabidiol is safe and effective at different doses as an additional treatment for pediatric drug-resistant epilepsy. Pure cannabidiol has potentially therapeutic properties, such as anti-convulsant effects, that may reduce seizure frequency. There are only a few open label studies that have demonstrated the safety and tolerance of cannabiodiol in both adult and pediatric epileptic populations--these studies were performed either retrospectively or with varying cannabidiol preparations. There are no well-documented studies and completely analyzed data for pediatric epileptic patients.
Detailed Description Not Provided
Study Type Expanded Access
Intervention Drug: Cannabidiol
Other Names:
  • CBD
  • Epidiolex
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status No longer available
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT03014440
Responsible Party Eric Marsh, MD, Children's Hospital of Philadelphia
Study Sponsor Eric Marsh, MD
Collaborators
  • University of Pittsburgh
  • Geisinger Clinic
Investigators Not Provided
PRS Account Children's Hospital of Philadelphia
Verification Date March 2017